SCHEMBL23728526

SCHEMBL23728526

CCOC(=O)c1cnn2cc(CC)cnc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
KDM4E B2RXH2 6/20 0.56
HPGD P15428 5/20 0.56
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
CSNK1D P48730 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
MAPT P10636 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
LMNA P02545 2/20 0.43
PDE2A O00408 2/20 0.43
HSD17B10 Q99714 3/20 0.43
KMT2A Q03164 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358103 0.87 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL17781274 0.87 KDM4E (0.57) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL23728550 0.86 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL23728540 0.85 PDE2A (0.43) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL14033079 0.85 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL23728472 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL309140 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL14033767 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL23728470 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDNPC1RAB9A
SCHEMBL23728467 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885KDM4E 190/4885HPGD 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.